Eric Coldwell
Stock Analyst at Baird
(3.89)
# 654
Out of 5,139 analysts
164
Total ratings
62.5%
Success rate
6.41%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Initiates: Outperform | $48 | $44.12 | +8.79% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $840.46 | +10.30% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $219.70 | -9.42% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $237.68 | +8.55% | 19 | Oct 29, 2025 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $16.50 | -15.15% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $182.61 | +22.67% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $189.49 | +2.38% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $212.45 | -4.45% | 13 | Aug 13, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $270.87 | +11.49% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $610.90 | -19.79% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $10.61 | +50.80% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $60.54 | -25.67% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $78.60 | -16.03% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.96 | +4,691.17% | 4 | Nov 10, 2017 |
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $44.12
Upside: +8.79%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $840.46
Upside: +10.30%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $219.70
Upside: -9.42%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $237.68
Upside: +8.55%
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $16.50
Upside: -15.15%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $182.61
Upside: +22.67%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $189.49
Upside: +2.38%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $212.45
Upside: -4.45%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $270.87
Upside: +11.49%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $610.90
Upside: -19.79%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $10.61
Upside: +50.80%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $60.54
Upside: -25.67%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $78.60
Upside: -16.03%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.96
Upside: +4,691.17%